Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
Breast cancer is a leading cause of cancer-related morbidity and mortality worldwide, with the highest incidence among women. Among the various subtypes of breast cancer, estrogen-receptor positive (ER+) is the most diagnosed. Estrogen upregulates cyclin D1, which in turn promotes the activity of CD...
Main Authors: | Fatima A Yousif, Abdulrahim A Alzain, Alhafez M Alraih, Walaa Ibraheem |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0291256 |
Similar Items
-
Molecular Docking of Aromatase Inhibitors
by: Virapong Prachayasittikul, et al.
Published: (2011-04-01) -
Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles
by: Alaa Edris, et al.
Published: (2023-04-01) -
Drug repurposing of clinically approved drugs to target epithelial-mesenchymal transition using molecular docking approach
by: Chun Hao, Ong, et al.
Published: (2023) -
Discovery of novel TMPRSS2 inhibitors for COVID-19 using in silico fragment-based drug design, molecular docking, molecular dynamics, and quantum mechanics studies
by: Abdulrahim A. Alzain, PhD, et al.
Published: (2022-01-01) -
Identification of novel TMPRSS2 inhibitors for COVID-19 using e-pharmacophore modelling, molecular docking, molecular dynamics and quantum mechanics studies
by: Abdulrahim A. Alzain, PhD, et al.
Published: (2021-01-01)